Q2 Earnings Forecast for CNTB Issued By HC Wainwright

Connect Biopharma Holdings Limited (NASDAQ:CNTB) – Investment analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Connect Biopharma in a report issued on Thursday, June 12th. HC Wainwright analyst B. Folkes expects that the company will post earnings of ($0.22) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($0.90) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.90) EPS, FY2028 earnings at ($0.67) EPS and FY2029 earnings at ($0.36) EPS.

Connect Biopharma (NASDAQ:CNTB) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.07.

Connect Biopharma Price Performance

Shares of Connect Biopharma stock opened at $0.95 on Monday. Connect Biopharma has a 52 week low of $0.51 and a 52 week high of $1.73. The business has a 50 day moving average price of $0.77 and a 200-day moving average price of $0.89.

Hedge Funds Weigh In On Connect Biopharma

An institutional investor recently bought a new position in Connect Biopharma stock. Choreo LLC acquired a new stake in shares of Connect Biopharma Holdings Limited (NASDAQ:CNTB) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 160,867 shares of the company’s stock, valued at approximately $204,000. Choreo LLC owned 0.29% of Connect Biopharma at the end of the most recent quarter. Institutional investors and hedge funds own 58.72% of the company’s stock.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.